View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 15, 2015

Cleveland Clinic to conduct first uterus transplant trial in US

Ohio-based Cleveland Clinic has revealed plans to conduct the first-ever clinical uterus transplant trial in the US.

Pregnant

Ohio-based Cleveland Clinic has revealed plans to conduct the first-ever clinical uterus transplant trial in the US.

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

In September, the clinic began screening candidates, aged 21 to 39, who suffer from uterine factor infertility (UFI).

UFI is a condition in women who cannot become pregnant because they were born without, have lost, or have a uterus that no longer functions.

A research study has been launched with the first transplant expected to take place in the next few months. The clinic will perform uterus transplants in ten women with UFI.

Cleveland Clinic Dr Tommaso Falcone said: "Although there appears to be potential for treating UFI with uterine transplantation, it is still considered highly experimental.

"Cleveland Clinic has a history of innovation in transplant and reproductive surgery and will explore the feasibility of this approach for women in the US."

Each candidate approved for the study will follow a protocol that involves stimulating ovaries to produce multiple eggs. These eggs will be retrieved, fertilised in a laboratory, and frozen.

Selected by organ procurement agency Lifebanc, a donor uterus will be transplanted within six to eight hours into the patient’s pelvis.

"Although there appears to be potential for treating UFI with uterine transplantation, it is still considered highly experimental."

After a year-long healing period, the frozen embryos will be implanted into the patient until she becomes pregnant.

The baby is delivered by caesarean section. After one or two babies have been delivered, hysterectomy will be performed on the patient to remove the transplanted uterus.

Cleveland Clinic lead investigator Andreas Tzakis said: "Unlike any other transplants, they are ‘ephemeral’.

"They are not intended to last for the duration of the recipient’s life, but will be maintained for only as long as is necessary to produce one or two children."

Last month, the UK’s Health Research Authority gave approval for womb transplants in a clinical trial by London’s Imperial College Healthcare.

In 2014, the world’s first successful uterus transplant birth occurred in Sweden.


Image: Pregnant woman at a WIC clinic in Virginia, US. Photo: courtesy of Ken Hammond (USDA).

Related Companies

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena